The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Radiofrequency Ablation of Hepatocellular Carcinoma as First-Line Treatment: Long-term Results and Prognostic Factors in 162 Patients with Cirrhosis
Abstract
PURPOSE: To evaluate the long-term outcomes of radiofrequency ablation (RFA) as a first-line therapy for early-stage hepatocellular carcinoma (HCC) and determine the prognostic factors for survival. MATERIALS AND METHODS: The institutional review board approved this retrospective study. From January 2006 to December 2007, 162 consecutive patients with cirrhosis (Child-Pugh class A and B, 137 and 25 patients, respectively) who underwent RFA as a first-line treatment for up to three HCCs with a maximum diameter of 5 cm (182 HCCs; mean diameter ± standard deviation, 2.59 cm ± 0.79; 17 multinodular forms) were included. After a mean follow-up of 50.3 months ± 19.9, results were analyzed for tumor recurrence, as well as overall and recurrence-free survival time. The Kaplan-Meier method and Cox proportional hazards regression model were used to evaluate the prognostic factors. RESULTS: The cumulative incidence of local tumor progression (LTP) was 14.5% at 5 years, with tumor size as the only significant predictive factor (relative risk = 2.13, P = .007). Overall 5-year survival and recurrence-free survival rates were 67.9% and 25.9%, respectively. Significant predictive factors for poor overall survival were Child-Pugh class B (relative risk = 2.43, P = .011), serum α-fetoprotein level (relative risk per 100 units = 1.01; P < .001), and presence of portosystemic collaterals (relative risk = 2.15, P = .025). The development of LTP significantly shortened median recurrence-free survival (28.0 months without LTP vs 12.0 months with LTP) and necessitated a higher number of interventional procedures (2.2 sessions without LTP vs 5.1 sessions with LTP). CONCLUSION: RFA is a safe and effective first-line treatment for early-stage HCC, with a 5-year survival rate of 67.9%. High serum α-fetoprotein level, advanced Child-Pugh class, and presence of portosystemic collateral vessels had a significant negative effect on overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Llovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708
Chen, M.-S., Li, J.-Q., Zheng, Y., Guo, R.-P., Liang, H.-H., Zhang, Y.-Q., Lin, X.-J., & Lau, W. Y. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000201480.65519.b8 · Cited by 1,432
(2012) · Hepatogastroenterology · doi:10.5754/hge11893 · Cited by 1,338
Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria
Goldberg, S. N., Grassi, C. J., Cardella, J. F., Charboneau, J. W., Dodd, G. D., Dupuy, D. E., Gervais, D., Gillams, A. R., Kane, R. A., Lee, F. T., et al. (2005) · Radiology · doi:10.1148/radiol.2353042205 · Cited by 1,193
Livraghi, T., Meloni, F., Di Stasi, M., Rolle, E., Solbiati, L., Tinelli, C., & Rossi, S. (2008) · Hepatology · doi:10.1002/hep.21933 · Cited by 1,103
Bruix, J., Castells, A., Bosch, J., Feu, F., Fuster, J., Garcia-Pagan, J., Visa, J., Bru, C., & Rodes, J. (1996) · Gastroenterology · doi:10.1016/s0016-5085(96)70070-7 · Cited by 895
Lencioni, R., Cioni, D., Crocetti, L., Franchini, C., Pina, C. D., Lera, J., & Bartolozzi, C. (2005) · Radiology · doi:10.1148/radiol.2343040350 · Cited by 867
One Thousand Fifty-Six Hepatectomies Without Mortality in 8 Years
Imamura, H. (2003) · Archives of Surgery · doi:10.1001/archsurg.138.11.1198 · Cited by 835
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
Galle, P. R., Foerster, F., Kudo, M., Chan, S. L., Llovet, J. M., Qin, S., Schelman, W. R., Chintharlapalli, S., Abada, P. B., Sherman, M., et al. (2019) · Liver International · doi:10.1111/liv.14223 · Cited by 597
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations
Nault, J.-C., Sutter, O., Nahon, P., Ganne-Carrié, N., & Séror, O. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.004 · Cited by 395
Huang, T.-Y., Huang, G.-L., Zhang, C.-Y., Zhuang, B.-W., Liu, B.-X., Su, L.-Y., Ye, J.-Y., Xu, M., Kuang, M., & Xie, X.-Y. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00001 · Cited by 361
Metadata
- Authors
- Lee, D. H., Lee, J. M., Lee, J. Y., Kim, S. H., Yoon, J. H., Kim, Y. J., Han, J. K., & Choi, B. I.
- Venue
- Radiology
- Published
- 2014-03
- Volume
- 270
- Issue
- 3
- Pages
- 900-909
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2142852085
- Cited by
- 308
- References
- 37
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiofrequency Ablation of Hepatocellular Carcinoma as First-Line Treatment: Long-term Results and Prognostic Factors in 162 Patients with Cirrhosis. https://app.cochat.ai/papers/10.1148/radiol.13130940
- The paper
- Lee, D. H., Lee, J. M., Lee, J. Y., Kim, S. H., Yoon, J. H., Kim, Y. J., Han, J. K., & Choi, B. I. (2014). Radiofrequency Ablation of Hepatocellular Carcinoma as First-Line Treatment: Long-term Results and Prognostic Factors in 162 Patients with Cirrhosis. Radiology. https://doi.org/10.1148/radiol.13130940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.